Related Experiment Video
Updated: Sep 17, 2026

Engineering Transplantation-suitable Retinal Pigment Epithelium Tissue Derived from Human Embryonic Stem Cells
Published on: September 6, 2018
The Biology and Cell Engineering of Retinal Pigment Epithelium Cell Transplantation: Developing a Living Drug
Sudipta Mahato1, Elena Daniele1, Colby F Lewallen1
1Ocular and Stem Cell Translational Research Section, National Eye Institute, National Institutes of Health, Bethesda, Maryland, USA; email: fnu.ruchi2@nih.gov, kapil.bharti@nih.gov.
Abstract:
Age-related macular degeneration (AMD) is a multifactorial retinal disease that causes progressive vision loss, with retinal pigment epithelium (RPE) atrophy representing a key initiating event. The RPE monolayer plays a crucial role in maintaining photoreceptor and choriocapillaris health and function. In advanced AMD stages, degeneration extends to the photoreceptors and choriocapillaris, likely as a consequence of preceding RPE atrophy. Existing treatment modalities aim to slow disease progression rather than restore degenerated cells and improve visual function. Pluripotent stem cell-derived RPE cell replacement therapy has emerged as a promising approach for restoring native retinal structure and visual function. This review provides an overview of RPE biology and function, clinical-grade manufacturing of RPE transplants, quality control considerations, and the use of scaffolds to improve delivery and integration. We also summarize preclinical and clinical studies that assess the safety, efficacy, and translational potential of RPE transplantation for AMD and other retinal degenerative conditions.
More Related Videos
12:45Development of a Refined Protocol for Trans-scleral Subretinal Transplantation of Human Retinal Pigment Epithelial Cells into Rat Eyes
Published on: August 12, 2017
06:04Performing Subretinal Injections in Rodents to Deliver Retinal Pigment Epithelium Cells in Suspension
Published on: January 23, 2015